What does this research mean for the field?

Endogenous GLP-1 levels are significantly elevated in Alzheimer's disease, increasing progressively with disease severity, and serve as a multidimensional biomarker reflecting neuroinflammation, amyloid deposition, and cognitive decline. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate endogenous glucagon-like peptide-1 (GLP-1) levels across the Alzheimer's disease spectrum and determine their relationships with neuroinflammation, amyloid and tau pathology, and cognitive impairment.

September 2, 2026General PsychiatryOpen Access

Elevated endogenous glucagon‐like peptide‐1 as a novel Alzheimer's disease biomarker associated with neuroinflammation and Aβ pathology

View Full Paper

Ask AI

Bookmark

Authors

JLJianping Li CJChenhui Ji JWJintao Wang

Discussion

Member takes

Overview

Cohort study reveals elevated serum glucagon-like peptide-1 correlates with neuroinflammation in Alzheimer disease, indicating an insufficient compensatory response.

Key Points

To evaluate endogenous glucagon-like peptide-1 (GLP-1) levels across the Alzheimer's disease spectrum and determine their relationships with neuroinflammation, amyloid and tau pathology, and cognitive impairment.
Analyzed two independent cohorts (Renji: n = 123; SheMountain: n = 127) comprising cognitively unimpaired adults, individuals with mild cognitive impairment, and patients with Alzheimer's disease dementia.
Quantified serum biomarkers (GLP-1, GFAP, Aβ40, Aβ42, pTau217) and postmortem brain tissue expression in the prefrontal cortex and hippocampus, alongside APOE genotyping, MRI, and Aβ-PET imaging.
Evaluated biomarker relationships using partial correlations, serial mediation models, and machine learning diagnostic classification algorithms.
Endogenous GLP-1 expression was significantly elevated in brain tissue and serum in Alzheimer's disease compared to controls, rising progressively across the continuum from normal cognition to dementia.
Serum GLP-1 correlated inversely with Montreal Cognitive Assessment performance and positively with GFAP, pTau217, and brain amyloid burden, statistically mediating the pathway between amyloid and tau pathology.
Diagnostic machine learning models combining GLP-1 with other fluid biomarkers yielded strong diagnostic accuracy (area under the curve = 0.896).

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a97e2eac562ede874ec7557 https://doi.org/10.1002/gps3.70052

View Full Paper

Ask AI

Bookmark

September 2, 2026General PsychiatryOpen Access

Elevated endogenous glucagon‐like peptide‐1 as a novel Alzheimer's disease biomarker associated with neuroinflammation and Aβ pathology

View Full Paper

Ask AI

Bookmark

Authors

JLJianping Li CJChenhui Ji JWJintao Wang

Discussion

Member takes

Overview

Cohort study reveals elevated serum glucagon-like peptide-1 correlates with neuroinflammation in Alzheimer disease, indicating an insufficient compensatory response.

Key Points

To evaluate endogenous glucagon-like peptide-1 (GLP-1) levels across the Alzheimer's disease spectrum and determine their relationships with neuroinflammation, amyloid and tau pathology, and cognitive impairment.
Analyzed two independent cohorts (Renji: n = 123; SheMountain: n = 127) comprising cognitively unimpaired adults, individuals with mild cognitive impairment, and patients with Alzheimer's disease dementia.
Quantified serum biomarkers (GLP-1, GFAP, Aβ40, Aβ42, pTau217) and postmortem brain tissue expression in the prefrontal cortex and hippocampus, alongside APOE genotyping, MRI, and Aβ-PET imaging.
Evaluated biomarker relationships using partial correlations, serial mediation models, and machine learning diagnostic classification algorithms.
Endogenous GLP-1 expression was significantly elevated in brain tissue and serum in Alzheimer's disease compared to controls, rising progressively across the continuum from normal cognition to dementia.
Serum GLP-1 correlated inversely with Montreal Cognitive Assessment performance and positively with GFAP, pTau217, and brain amyloid burden, statistically mediating the pathway between amyloid and tau pathology.
Diagnostic machine learning models combining GLP-1 with other fluid biomarkers yielded strong diagnostic accuracy (area under the curve = 0.896).

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a97e2eac562ede874ec7557 https://doi.org/10.1002/gps3.70052

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark